Hyderabad, Apr 14: Indian Pharmaceutical Alliance (IPA) has committed to providing quality medicines to patients in India and globally, particularly to those countries that are severely affected by the pandemic.
In a statement here on Tuesday, the IPA said, India and the world today are confronted with an unprecedented global health threat in the form of COVID 19. In the light of these challenging times, Indian Pharmaceutical Alliance (IPA) and its member companies are working in an integrated manner with the Government of India to ensure that patients in India and across the world continue to have access to quality medicines. India is recognised as the pharmacy of the world and our products are exported to more than 200 countries across the world.
Indian government’s position of international solidarity and cooperation is vital to deal with the COVID situation. The decision to withdraw restrictions on 12 products and export Hydroxychloroquine is a reflection of India’s commitment to supply medicines at this critical time. IPA lauds the Government of India’s positive move and is in line with the image of India as the pharmacy of the world. "
We have adequate manufacturing capacity, today, in the country and have sufficient supply to meet both domestic and export demand. Zydus Cadila and IPCA are the major manufacturers of hydroxychloroquine in the country. The companies are ramping up production to ensure an uninterrupted supply for the domestic and export market", the statement added. (UNI)